ReviewJournal of clinical pharmacy and therapeutics2022

No two classes of biosimilars: Urgent advice to the US Congress and the FDA.

Sarfaraz K NiaziPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.